Publications by authors named "Lovisa Friberg"
Article Synopsis
- Mineralocorticoid receptor antagonists (MRA) like spironolactone are effective for heart failure with reduced ejection fraction but are often underused due to hyperkalemia concerns.
- The REALIZE-K trial tested the effects of sodium zirconium cyclosilicate (SZC) in helping patients with heart failure and hyperkalemia effectively use spironolactone.
- Results showed that participants who received SZC had significantly better outcomes in terms of maintaining normal potassium levels and continuing on spironolactone compared to those on a placebo.
Background: Mineralocorticoid receptor antagonists (MRAs) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF). However, MRAs are often underused because of hyperkalemia concerns.
Objectives: The purpose of this study was to assess whether sodium zirconium cyclosilicate (SZC), a nonabsorbed crystal that traps and rapidly lowers potassium, enables MRA use in patients with HFrEF and prevalent hyperkalemia (or at high risk).
Objectives: To describe chronic kidney disease (CKD) regarding treatment rates, comorbidities, usage of CKD International Classification of Diseases (ICD) diagnosis, mortality, hospitalisation, evaluate healthcare utilisation and screening for CKD in relation to new nationwide CKD guidelines.
Design: Population-based observational study.
Setting: Healthcare registry data of patients in Southwest Sweden.